Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono, +21

New England Journal of Medicine

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, +20

JAMA

A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy

Thomas Klopstock, Patrick Yu‐Wai‐Man, Konstantinos Dimitriadis, +15

Brain

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Heikki Joensuu, Petri Bono, Vesa Kataja, +17

Journal of Clinical Oncology

Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease

C. Warren Olanow, Karl Kieburtz, Olivier Rascol, +6

Movement Disorders

KinesiologyHealth SciencesParkinson DiseaseL-dopa DoseClinical Trials +11

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

Torbjörn Kullenberg, Malin Löfqvist, Mika Leinonen, +2

Lara D. Veeken

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

C. Warren Olanow, Stewart A. Factor, Alberto J. Espay, +10

The Lancet Neurology

Placebo-controlled Phase 3Parkinson DiseaseClinical NeurologyAphasiaNeuroscience +4

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, +17

Journal of Clinical Oncology

Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids

Craig M. McDonald, Heather Gordish‐Dressman, Erik Henricson, +44

Neuromuscular Disorders

AsthmaKinesiologyGc TreatmentAdvanced Lung DiseasePulmonary Care +12

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Andrew McGarry, Shane Rosanbalm, Mika Leinonen, +25

The Lancet Neurology

Untreated ParkinsonNeurodegenerative DiseasesParkinson DiseaseClinical NeurologyPlacebo-controlled Trial +3